Eduardo de Santibañes

Eduardo de Santibañes

Auto-generated profile, based on publicly available information

Eduardo de Santibañes

Hospital Italiano de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
KSKazunari Sasaki
Kazunari Sasaki
JGJohan Gagnière
Johan Gagnière
ADAurélien Dupré
Aurélien Dupré
VAVictoria Ardiles
Victoria Ardiles
JOJuan Manuel O'COnnor
Juan Manuel O'COnnor
JOJuan O´connor
Juan O´connor

1 January 2014 in JSLS : Journal of the Society of Laparoscopic & Robotic Surgeons
Verified
Journal Article
Open access
ADAgustin Dietrich
Agustin Dietrich
FAFernando Alvarez
Fernando Alvarez
NRNicolas Resio
Nicolas Resio
OMOscar Mazza
Oscar Mazza
ESEduardo de Santibañes
Eduardo de Santibañes
MSMartin de Santibanes
Martin de Santibanes
To date, the management of common bile duct stones (CBDs) is still controversial. If laparoscopic exploration is performed and biliary decompression is needed after stone removal, the placement of a laparoscopic transpapillary stent shows promising results in avoiding T-tube-related complications. Between January 2007 and May 2012, a series of 48 patients who underwent biliary decompression after laparoscopic common bile duct exploration (LCBDE) to treat choledocholithiasis was retrospectively analyzed. The results in patients with transpapillary stent placement (TS=35) were compared with those who had an external biliary drainage (EBD=13). LCBDE and TS placement was achieved either by a choledochotomy or through the cystic duct. There was no mortality in our series. Patients with an external biliary drainage (EBD) had more surgery-related complications (P<.0001) and a longer hospital stay (P=.03). Postoperative ERCP to remove the TS was successful in all cases. Laparoscopic TS is a safe method in the treatment of selected patients with CBD stones that can be achieved without having to perform a choledochotomy. Because of the lower morbidity and the shorter hospital stay compared with EBD, it should be considered as a first approach whenever biliary decompression is needed after LCBDE.

1 October 2021 in HPB
Verified
Journal Article
Closed access
TRTim Reese
Tim Reese
GMGeorgios Makridis
Georgios Makridis
DRDimitri Aristotle Raptis
Dimitri Aristotle Raptis
MMMassimo Malagó
Massimo Malagó
RHRoberto Hernandez-Alejandro
Roberto Hernandez-Alejandro
Karl J. OldhaferKarl J. Oldhafer
Karl J. Oldhafer

24 April 2020 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
JGJuan Glinka
Juan Glinka
VAVictoria Ardiles
Victoria Ardiles
JPJuan Pekolj
Juan Pekolj
JMJuan Mattera
Juan Mattera
RCRodrigo Sanchez Clariá
Rodrigo Sanchez Clariá
MSMartin de Santibanes
Martin de Santibanes

4 January 2022 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
LCLucas José Caram
Lucas José Caram
FCFrancisco Calderon
Francisco Calderon
EMEsteban Masino
Esteban Masino
VAVictoria Ardiles
Victoria Ardiles
EMEzequiel Mauro
Ezequiel Mauro
MSMartin de Santibanes
Martin de Santibanes
Lucas José Caram, Francisco Calderon, Esteban Masino, Victoria Ardiles, Ezequiel Mauro, Leila Haddad, Juan Pekolj, Jimena Vicens, Adrian Gadano, Eduardo de Santibañes, Martín de Santibañes. Ann Hepatobiliary Pancreat Surg 2022;26:40-6. https://doi.org/10.14701/ahbps.21-094

20 June 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JOJ. O’cOnnor
J. O’cOnnor
EHE. Huertas
E. Huertas
FLF. Sanchez Loria
F. Sanchez Loria
FBF. Brancato
F. Brancato
JGJ. Grondona
J. Grondona
ESE. de Santibañes
E. de Santibañes
Introduction: Even though RAS mutations are known to imply aggressive tumour biology, their objective impact on survival is still controversial. The purpose of this study is to determine the impact of KRAS mutational status in the overall survival (OS) and recurrence free survival (RFS) of patients undergoing surgery for colorectal liver metastases (CLM).